A Five Part Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetic (PK) Profile of Single and Repeat Oral Doses of FDL176 in Healthy and Cystic Fibrosis (CF) Participants
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2018
At a glance
- Drugs FDL 176 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man; Pharmacokinetics
- 01 Jul 2018 Status changed from recruiting to completed.
- 11 Apr 2018 Planned End Date changed from 5 Mar 2018 to 29 Jun 2018.
- 11 Apr 2018 Planned primary completion date changed from 5 Mar 2018 to 29 Jun 2018.